Cargando…

Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma

Brentuximab vedotin (SGN-35) is an antibody–drug conjugate with a high selectivity against CD30(+) cell lines and more than 300-fold less activity against antigen-negative cells. In the last years, the results of many in vitro and in vivo studies have led to the fast approval of this drug to treat l...

Descripción completa

Detalles Bibliográficos
Autores principales: Esser, Laura, Weiher, Hans, Schmidt-Wolf, Ingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964432/
https://www.ncbi.nlm.nih.gov/pubmed/27376285
http://dx.doi.org/10.3390/ijms17071056